The Clinical Value Of Galectin-3Concentration In Prostatic Fluid For The Diagnosis And Treatment Of Prostate Cancer

Objective: To study the concentration of Galectin-3in prostatic fluid for thediagnosis of prostate cancer, as well as identification of the clinical value ofprogression and metastasis of prostate cancerMethods:31men suspicious of prostate cancer were enrolled as experimentalsubjects. Transrectal ultrasound-guided prostate biopsies were performed andbefore that a transrectal prostate massage was taken for getting prostatic fluid.Measured by ELISA using polyclonal antibody, Galectin-3concentrations inprostatic fluid were determined. And Galectin-3expression level was measureusing human Galectin-3antibody immunohistochemical staining of biopsytissue. The differences of Galectin-3concentration were compared betweenbenign prostatic hyperplasia group and prostate cancer group.Results: the results revealed ages and prostate volumes were not statisticallydifferent between prostate cancer and benign prostatic hyperplasia group. ButPSA and PSAD had statistically significant differences, which of prostatecancer group were greater than BPH. Galectin-3concentrations in prostaticfluid of prostate cancer group were also higher than benign prostatichyperplasia group (P <0.001).12prostate cancer patients, of whom there arefour people with metastatic bone scintigraphy images, showing a higherGalectin-3concentration in metastatic patients than that of other prostatecancer. However, Galectin-3had no significant correlation with Gleasson score, PSA or PSAD. Area under the ROC curve of Galectin-3was the largestof0.921, which meant Galectin-3had a greater value of diagnosis of prostatecancer than PSA and PSAD. When Galectin-3concentration was4167ug/ml,the sensitivity was100%and the specificity was80%. Immunohistochemistryfurther showed, Galectin-3expression in prostate cancer was greater thanBPH group, having a statistically difference.Conclusion: Galectin-3concentration in prostatic fluid of patients withprostate cancer were significantly higher than those of benign prostatichyperplasia. Moreover, prostate cancer patients with bone metastasis hadgreater Galectin-3concentrations than those without metastasis. Therefore,Galectin-3concentration in prostatic fluid can not only be beneficial as adiagnostic indicator of prostate cancer, may also be used to determine thepresence of metastatic prostate cancer, and to guide treatment and prognosisinferred.